Hint | Food | ¸À°úÇâ | Diet | Health | ºÒ·®Áö½Ä | ÀÚ¿¬°úÇÐ | My Book | À¯Æ©ºê | Frims | ¿ø ·á | Á¦ Ç° | Update | Site |
¼ö¿ëü ¡í GPCR ¡í µ¶°ú¾à ¡í Shape drug design(ÇüÅÂ,¿ëÇصµ) drug design : µ¶°ú¾à - ½Å¾à °³¹ß È®·ü - GPCR ¿ªÇÒ : ½Å¾à °³¹ßÀÇ µ¹Æı¸ : ¾à¹° ÀÛ¿ëÀÇ Àý¹Ý - ¾àÀÇ ºÐÀÚÇüÅ QSAR - °í¾Æ GPCR - ºÐÀÚ·® : - ¿ëÇصµ : 1. Natural Products: MW ~400-1000 Structurally highly diverse, Often biologically active Optimization process is time consuming, High manufacturing costs 2. Synthetic compounds collections: M.W ~300-350. Drug-like, Structural diversity is limited Optimization process straightforward, Low manufacturing costs 3. Peptoids, peptides and peptidomimetics derived from a target protein : M.W >600 Fast assembly through linear assembly of similar¡¤building blocks Limited,¡°rather flexible¡± diversity. Usually not ¡°drug-like¡±, Optimization process often long and tedious 4. Small-molecular-weight compound libraries from combinatorial and parallel chemistry: Molecular weight <600. Fast and convergent assembly using reactive building blocks Limited chemica1and structural diversity ¡°Drug-like¡±, Fast optimization process, Low manufactoring costs |
||||
|
|
|||